Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications... Show more
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Momentum Indicator moved above the 0 level on July 17, 2025. You may want to consider a long position or call options on BITGF as a result. In of 14 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BITGF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.042) is normal, around the industry mean (10.661). P/E Ratio (45.965) is within average values for comparable stocks, (62.050). BITGF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.847). Dividend Yield (0.011) settles around the average of (0.016) among similar stocks. P/S Ratio (5.974) is also within normal values, averaging (83.916).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BITGF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Industry PharmaceuticalsOther
A.I.dvisor tells us that BITGF and TMCI have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BITGF and TMCI's prices will move in lockstep.
Ticker / NAME | Correlation To BITGF | 1D Price Change % | ||
---|---|---|---|---|
BITGF | 100% | N/A | ||
TMCI - BITGF | 22% Poorly correlated | +7.92% | ||
VRCDF - BITGF | 21% Poorly correlated | N/A | ||
SNWV - BITGF | 9% Poorly correlated | +15.85% | ||
ICCM - BITGF | 6% Poorly correlated | -7.21% | ||
CHEOF - BITGF | 5% Poorly correlated | N/A | ||
More |
Ticker / NAME | Correlation To BITGF | 1D Price Change % |
---|---|---|
BITGF | 100% | N/A |
Pharmaceuticals: Other industry (105 stocks) | -0% Poorly correlated | -0.37% |
Pharmaceuticals industry (394 stocks) | -4% Poorly correlated | +0.40% |